Matches in SemOpenAlex for { <https://semopenalex.org/work/W2306410245> ?p ?o ?g. }
- W2306410245 abstract "Abstract Background Multiple myeloma (MM) therapies are becoming increasingly effective with deeper responses. Indeed, recent prospective clinical trials based on carfilzomib, lenalidomide and dexamethasone (CRd) show complete response (CR)/near (n)-CR rates of over 75%. Consequently, newer techniques are needed to detect minimal residual disease (MRD). We are conducting a prospective Phase II clinical trial studying response to CRd in newly diagnosed MM patients. We assessed treatment responses obtained by traditional IMWG response criteria, MRD measurement by 8-color multiparameter flow cytometry (MFC) based on a minimum of 3 million events (maximum detection rate: 0.0005%), and MRD measurement by high throughput sequencing in 14 newly diagnosed MM patients who achieved very good partial response (VGPR)/CR/nCR. Methods Bone marrow (BM) and/or plasma samples were obtained from 14 newly diagnosed MM patients receiving CRd therapy. Samples were subjected to deep sequencing using the LymphoSIGHT™ platform, which has a sensitivity to detect one cancer cell per million leukocytes in peripheral blood (Faham et al, Blood 2012). Briefly, using universal primer sets, we amplified immunoglobulin heavy and kappa chain (IGH and IGK) variable, diversity, and joining gene segments from genomic DNA obtained from CD138+ BM cell lysate at baseline, as well as post-treatment plasma samples. Amplified products were sequenced and analyzed using standardized algorithms for clonotype determination. Myeloma-specific clonotypes were identified for each patient based on their high frequency within the B-cell repertoire in the CD138+ cell lysate BM sample. The presence of the myeloma-specific clonotype was then quantified in plasma samples obtained post-treatment. A quantitative and standardized measure of clone level among all leukocytes in the sample was determined using internal reference DNA. For patients who achieved VGPR/CR/nCR, we compared the results from MFC of the BM with those obtained by sequencing the cell free DNA in plasma samples. Results We detected a high frequency myeloma-specific gene rearrangement in 13 of 14 (93%) CD138+ BM cell lysate samples obtained at diagnosis. We assessed for MRD by flow cytometry and deep sequencing for the seven patients who were in VGPR/CR/nCR based on traditional protein response criteria. One patient was MRD positive by flow cytometry of the marrow and negative by deep sequencing in blood. Another patient was MRD positive by deep sequencing but negative by flow cytometry. Additionally, in the diagnostic BM sample of one patient, we observed two distinct high-frequency IGH clones that were related through a process of somatic hypermutation. The specific mutation pattern observed is consistent with a branched model of evolution where the two observed clones did not evolve from each other but rather from a common ancestor. We are currently analyzing samples collected at baseline and post-treatment in an additional 23 MM patients enrolled on the CRd trial, and results will be presented. Conclusions The development of sensitive, non-invasive MRD assays is becoming increasingly important to assess the impact of modern anti-myeloma therapies. One novel approach for MRD detection, termed the LymphoSIGHT™ platform, relies on high-throughput sequencing of VDJ rearrangements at the immunoglobulin locus. Based on our CRd clinical trial for newly diagnosed MM patients, we found sequencing of cell free tumor DNA in bone marrow aspirates and peripheral blood (plasma) to be technically feasible. Among 6 patients who obtained VGPR/CR/nCR and were found to be MRD negative by MFC of the BM, we found one patient to be MRD positive by sequencing in the peripheral blood (plasma compartment). One patient was MRD positive by flow cytometry but negative by deep sequencing. These preliminary results suggest that a sequencing-based MRD blood test may be more sensitive than standard protein response criteria and complementary to MFC-based BM tests. Analysis of additional samples will be presented. Disclosures: Faham: Sequenta: Employment, Equity Ownership, Membership on an entity’s Board of Directors or advisory committees. Weng:Sequenta, Inc.: Employment, Equity Ownership. Moorhead:Sequenta, Inc.: Employment, Research Funding." @default.
- W2306410245 created "2016-06-24" @default.
- W2306410245 creator A5002571777 @default.
- W2306410245 creator A5005077693 @default.
- W2306410245 creator A5010930696 @default.
- W2306410245 creator A5014636271 @default.
- W2306410245 creator A5016656825 @default.
- W2306410245 creator A5017057018 @default.
- W2306410245 creator A5023786439 @default.
- W2306410245 creator A5044366730 @default.
- W2306410245 creator A5044681793 @default.
- W2306410245 creator A5045179755 @default.
- W2306410245 creator A5046553822 @default.
- W2306410245 creator A5046878636 @default.
- W2306410245 creator A5048966043 @default.
- W2306410245 creator A5054118827 @default.
- W2306410245 creator A5060701531 @default.
- W2306410245 creator A5061379753 @default.
- W2306410245 creator A5062086023 @default.
- W2306410245 creator A5064222660 @default.
- W2306410245 creator A5065696086 @default.
- W2306410245 creator A5067074464 @default.
- W2306410245 creator A5079704265 @default.
- W2306410245 creator A5081837203 @default.
- W2306410245 creator A5082004555 @default.
- W2306410245 creator A5084491683 @default.
- W2306410245 creator A5086510250 @default.
- W2306410245 creator A5089952063 @default.
- W2306410245 date "2013-11-15" @default.
- W2306410245 modified "2023-10-01" @default.
- W2306410245 title "Minimal Residual Disease (MRD) Detection By Deep Sequencing In Newly Diagnosed Multiple Myeloma Patients Treated With Carfilzomib, Lenalidomide and Dexamethasone" @default.
- W2306410245 doi "https://doi.org/10.1182/blood.v122.21.1902.1902" @default.
- W2306410245 hasPublicationYear "2013" @default.
- W2306410245 type Work @default.
- W2306410245 sameAs 2306410245 @default.
- W2306410245 citedByCount "0" @default.
- W2306410245 crossrefType "journal-article" @default.
- W2306410245 hasAuthorship W2306410245A5002571777 @default.
- W2306410245 hasAuthorship W2306410245A5005077693 @default.
- W2306410245 hasAuthorship W2306410245A5010930696 @default.
- W2306410245 hasAuthorship W2306410245A5014636271 @default.
- W2306410245 hasAuthorship W2306410245A5016656825 @default.
- W2306410245 hasAuthorship W2306410245A5017057018 @default.
- W2306410245 hasAuthorship W2306410245A5023786439 @default.
- W2306410245 hasAuthorship W2306410245A5044366730 @default.
- W2306410245 hasAuthorship W2306410245A5044681793 @default.
- W2306410245 hasAuthorship W2306410245A5045179755 @default.
- W2306410245 hasAuthorship W2306410245A5046553822 @default.
- W2306410245 hasAuthorship W2306410245A5046878636 @default.
- W2306410245 hasAuthorship W2306410245A5048966043 @default.
- W2306410245 hasAuthorship W2306410245A5054118827 @default.
- W2306410245 hasAuthorship W2306410245A5060701531 @default.
- W2306410245 hasAuthorship W2306410245A5061379753 @default.
- W2306410245 hasAuthorship W2306410245A5062086023 @default.
- W2306410245 hasAuthorship W2306410245A5064222660 @default.
- W2306410245 hasAuthorship W2306410245A5065696086 @default.
- W2306410245 hasAuthorship W2306410245A5067074464 @default.
- W2306410245 hasAuthorship W2306410245A5079704265 @default.
- W2306410245 hasAuthorship W2306410245A5081837203 @default.
- W2306410245 hasAuthorship W2306410245A5082004555 @default.
- W2306410245 hasAuthorship W2306410245A5084491683 @default.
- W2306410245 hasAuthorship W2306410245A5086510250 @default.
- W2306410245 hasAuthorship W2306410245A5089952063 @default.
- W2306410245 hasConcept C126322002 @default.
- W2306410245 hasConcept C143998085 @default.
- W2306410245 hasConcept C203014093 @default.
- W2306410245 hasConcept C2776063141 @default.
- W2306410245 hasConcept C2776364478 @default.
- W2306410245 hasConcept C2779823535 @default.
- W2306410245 hasConcept C2780007613 @default.
- W2306410245 hasConcept C2780108899 @default.
- W2306410245 hasConcept C2780401358 @default.
- W2306410245 hasConcept C2781119759 @default.
- W2306410245 hasConcept C71924100 @default.
- W2306410245 hasConcept C90924648 @default.
- W2306410245 hasConceptScore W2306410245C126322002 @default.
- W2306410245 hasConceptScore W2306410245C143998085 @default.
- W2306410245 hasConceptScore W2306410245C203014093 @default.
- W2306410245 hasConceptScore W2306410245C2776063141 @default.
- W2306410245 hasConceptScore W2306410245C2776364478 @default.
- W2306410245 hasConceptScore W2306410245C2779823535 @default.
- W2306410245 hasConceptScore W2306410245C2780007613 @default.
- W2306410245 hasConceptScore W2306410245C2780108899 @default.
- W2306410245 hasConceptScore W2306410245C2780401358 @default.
- W2306410245 hasConceptScore W2306410245C2781119759 @default.
- W2306410245 hasConceptScore W2306410245C71924100 @default.
- W2306410245 hasConceptScore W2306410245C90924648 @default.
- W2306410245 hasLocation W23064102451 @default.
- W2306410245 hasOpenAccess W2306410245 @default.
- W2306410245 hasPrimaryLocation W23064102451 @default.
- W2306410245 hasRelatedWork W11718440 @default.
- W2306410245 hasRelatedWork W151938067 @default.
- W2306410245 hasRelatedWork W2045807214 @default.
- W2306410245 hasRelatedWork W2136898525 @default.
- W2306410245 hasRelatedWork W2409528737 @default.
- W2306410245 hasRelatedWork W2553582962 @default.
- W2306410245 hasRelatedWork W2560561384 @default.
- W2306410245 hasRelatedWork W2564698559 @default.
- W2306410245 hasRelatedWork W2579739608 @default.
- W2306410245 hasRelatedWork W2579879620 @default.